Stada Arzneimi Namen (STDAF) 50.1300 $STDAF Research and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stada Arzneimi Namen (STDAF) 50.1300 $STDAF

Research and Markets - Global Generic Drugs Market 2016 - Forecasts to 2020 with Teva, Sandoz, Allergan, Mylan, Sun Pharma & STADA Arzneimittel Dominating
PR Newswire Europe - Fri Jun 17, 10:10AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
AGN: 236.00 (+1.98)

From Teva Pharmaceuticals to STADA Arzneimittel - Technavio Unveils Top Six Vendors in the Global Generic Drugs Market from 2016 to 2020
BusinessWire - Tue May 31, 11:00AM CDT
Technavio has announced the top six leading vendors in their recent global generic drugs market report. This research report also lists 49 other prominent vendors that are expected to impact the market during the forecast period.

Pharmaceutical Industry in China 2015
M2 - Tue Nov 03, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/364v6j/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. This report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc. The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry. Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, this latest research is a collection of all you need to know about China's Pharmaceutical Industry. Key Topics Covered: A. Executive Summary B. The Global Pharmaceutical Industry - A Brief Profile C. China Pharmaceutical Industry D. OTC Pharmaceuticals in China E. Generics Sector in China F. Market Trends & Growth Opportunities G. Regulatory Developments & Framework H. China Pharmaceutical Industry - SWOT Framework Analysis I. China Pharmaceutical Industry - PEST Framework Analysis J. China Pharmaceutical Industry - Porter's Five Forces Business Strategy Analysis K. Evolving Strategic Options for Chinese Companies L. Impact of Changing IP Laws on Product Level Access to Medicines in China M. Investment Options in China's Pharmaceutical Industry N. China's WTO Accession - Challenges & Opportunities O. Contract Research Services in China's Pharma Sector P. China's Pharmaceutical Industry - Future Perspective Q. Major Industry Players - AstraZeneca PLC - Bayer AG - Beijing Double-Crane Pharmaceutical (DCPC) - Beijing TongRenTang Co., Ltd. - GlaxoSmithKline Plc - Guilin Sanjin Pharmaceutical Co., Ltd. - Northeast Pharmaceutical Group (NEPG) - Novartis AG - Pfizer Inc - Roche Holding AG - Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL) - Shanghai Pharmaceutical (Group) Co. Ltd (SPCL) - STADA Arzneimittel - Wuhan Grand Pharmaceutical - Yunnan Baiyao Group Co., Ltd. For more information visit http://www.researchandmarkets.com/research/36...maceutical
PFE: 35.81 (+0.24), AZN: 30.15 (-0.27), GSK: 43.50 (+0.33), NVS: 81.72 (-0.99)

Pediculosis (Head Lice Infestation) - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bdrs/pediculosis_head) has announced the addition of the "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" report to their offering. "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" provides data on the Pediculosis (Head Lice Infestation) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pediculosis (Head Lice Infestation). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pediculosis (Head Lice Infestation). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pediculosis (Head Lice Infestation) Therapeutics Clinical Trials - Hatchtech Pty, Ltd - ParaPRO LLC - Stada Arzneimittel AG - Sun Pharmaceutical Industries Limited - Sanofi - Summers Laboratories Incorporated - Oystershell NV - Lybar, a.s. - EctoPharma Ltd. - Altman Biomedical Consulting Pty. Ltd - Mandacaru Foundation - Shiraz University of Medical Sciences - Assistance Publique Hopitaux De Marseille - Australian National University - Centers for Disease Control and Prevention - Hackensack University Medical Center - Royal Free London NHS Foundation Trust - South Florida Family Health And Research Centers - Tokyo University of Science For more information visit http://www.researchandmarkets.com/research/v2...losis_head

The Corporate Reputation of Pharma - The Global Patient Perspective in 2014
M2 - Thu Apr 16, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mv4rwp/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma - The Patient Perspective in 2014 - Global Edition " report to their offering. The Corporate Reputation of Pharmafrom a Patient Perspective' is now in its fourth edition. This report contains the latest version (2014 results; published early 2015). For each annual Corporate Reputation report, the author surveys a large number of patient groups worldwideinternational, national, and regional, from across many different disease and healthcare specialties. 1,150 patient groups from 58 countries participated in the Corporate Reputation's 4th edition. About the questionnaire: The methodology for assessing pharma corporate reputation from a patient perspective was first established by PatientView in 2010 following consultations with pharma, medical-device companies, tradesbodies and patient groups. The resulting questionnaire combines the priorities of patient groups (which have a better understanding of pharma than individual patients) and industry on the topic of corporate reputation. The same questions on corporate reputation are posed to respondent patient groups every year (though each year's respondent patient groups are not necessarily the same as those of the previous year). The answers help define what patients require from pharma companies, while acknowledging what pharma itself thinks it is capable of delivering. Since the questions do not deviate, the Corporate Reputation of Pharma allows the performance of individual pharma companies (and the industry as a whole) to be compared year on yearwhich, in turn, helps define appropriate strategies for improvement. I was torn between ethical, transparency, and patient safety. But, ultimately, patient safety is the most important to me and to our organization Global, US-based patient group focusing on cancer and palliative care Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 37 Companies - Profiles of 37 Companies - Profile of Respondents Companies Mentioned - AbbVie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer- Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - GSK - Gilead - Gr?nenthal - Ipsen - Janssen - Lundbeck - Menarini - Merck & Co - Mylan - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shire - Stada Arzneimittel - Takeda - Teva - UCB For more information visit http://www.researchandmarkets.com/research/mv..._corporate
AGN: 236.00 (+1.98), BIIB: 242.03 (-3.03), NVO: 54.23 (-0.04), BAX: 45.31 (-0.14), MRK: 58.00 (+0.06), AMGN: 154.27 (-0.01), LLY: 79.64 (+0.69), BMY: 73.78 (unch), NVS: 81.72 (-0.99), CELGZ: 1.35 (-0.05)

Europe Biosimilars Market & Pipeline Insight 2014
M2 - Tue Oct 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bblsk8/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time. One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015. The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules. Europe Biosimilars Market & Pipeline Insight Report Highlights: - Biosimilars Market Overview & Trend Analysis by Country - Biosimilars Introduction Timeline in Europe - Biosimilars Development & Market Authorization Guidelines - Biosimilars Clinical Pipeline by Phase, Indication, Company & Country - Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country - Europe Biosimilars Pipeline: 93 Biosimilars - Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine) Key Topics Covered: 1. Europe Biosimilars Market Overview 2. Europe Biosimilars Market Trend Analysis by Country 3. Biosimilars Introduction Timeline in Europe 4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario 5. Europe Biosimilars Market Dynamics 6. Future Prospectus of Biosimilars in Europe 7. Regulatory & Approval Authorities: EMA & CHMP 8. Biosimilars Development & Market Authorization Guidelines 9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country 10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country 11. No Development Reported in Biosimilars Clinical Pipeline 12. Competitive Landscape - Apotex - Celltrion Healthcare - Finox Biotech - Hexal - Hospira - Medice Arzneimittel P?tter - Sandoz - Stada Arzneimittel - Teva Pharma For more information visit http://www.researchandmarkets.com/research/bblsk8/europe

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 39

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 216

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 0

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 229

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding JD.com's Options Activity and Market Trends

Updated Category News Views 250

JD.com's Options Activity Overview Financial giants are making notable bullish moves regarding JD.com. Our detailed analysis of options history for JD.com (NASDAQ: JD) has identified several unusual trades that highlight prevailing market sentiments. Breakdown of Trader Sentiment A closer examination of the activity reveals that 60% of traders are bullish, while 40%...

Continue Reading
Wells Fargo Invests in Nuclear Energy Amid AI-Powered Demand Surge

Updated Category News Views 293

Wells Fargo's Strategic Bet on Nuclear Energy Wells Fargo Investment Institute is strategically investing in nuclear energy as a pivotal solution to drive the U.S. economy forward. This decision mirrors the positive outlook from various investment analysts and experts, who note escalating electricity demand. Anticipating a Surge in U.S. Power Demand The firm has recently...

Continue Reading
Costco to Expand with Four New Locations by End of 2024

Updated Category News Views 429

Costco's Future Expansion Plans If you love the incredible value that Costco provides, there's some exciting news ahead. The company is preparing to open four new warehouse locations across the U.S. by the end of this year. With their well-known selection of bulk products, even more shoppers will have the chance to enjoy these retail giants. New Location Details...

Continue Reading
Heineken 0.0 Campaign Challenges Social Stigmas on Drinking

Updated Category News Views 617

Heineken 0.0 Campaign Challenges Perceptions of Non-Alcoholic Choices In today's evolving society, drinking habits are undergoing significant transformation. The longstanding habits surrounding alcohol consumption are being reevaluated, inspiring brands like Heineken® to adapt their marketing strategies. A recent study indicated that despite the increasing popularity of...

Continue Reading
Revolutionizing Cancer Monitoring: DELFI Diagnostics' Innovations

Updated Category News Views 309

Revolutionizing Cancer Monitoring Technology at AACR Meeting DELFI Diagnostics, a pioneer in fragmentomics, is set to present innovative solutions for early cancer detection and treatment monitoring at a prominent oncology research event. Their advanced technologies, which leverage the analysis of cell-free DNA (cfDNA), promise to enhance both the screening process for...

Continue Reading